Biochrom, Gilson Sign ELISA Distribution Agreement
News Jun 10, 2014
The partnership combines the strength of the EZ Read range of microplate readers from Biochrom, with Gilson’s innovative line of liquid handling systems. Used together the flexible offering enables scientists to easily automate their absorbance assays including ELISA, total protein and cell viability.
Biochrom created the EZ Read microplate reader range by matching its expertise in absorbance measurement with requests from scientists and technicians to make their experimental workflow easier and more effective. Gilson has incorporated its vast knowledge of liquid transfer techniques into a wide range of automated liquid handlers.
Tristana von Will, Global Product Marketing Manager at Biochrom, commented: “Gilson is a leader in liquid handling systems and we are delighted to be combining the heritage and expertise of both companies to co-sell our product ranges. Researchers and technicians will be very familiar with both the Biochrom and Gilson brands, but together we can further streamline experimental workflows for our customers.”
Ronan Herry, European Marketing Director at Gilson International BV, stated:” The Biochrom range of EZ Read Microplate readers fits very well with our range of liquid handling products, either for those customers who require manual or electronic multichannel pipettes from the PIPETMAN range or for those customers that would like to automate their lab work flows. The Gilson PIPETMAX comes at a size and price that is accessible to any lab and takes away the stress and strain of manual pipetting for ELISA and Bradford type assays while improving reproducibility. Adding the Biochrom range now enables Gilson to offer a complete applications solution for our customers”.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE